White matter hyperintensities predict amyloid increase in Alzheimer's disease

Impaired amyloid clearance probably contributes to increased amyloid deposition in sporadic Alzheimer's disease (AD). Diminished perivascular drainage due to cerebral small-vessel disease (CSVD) has been proposed as a cause of reduced amyloid clearance. White matter hyperintensities (WMHs) are considered to reflect CSVD and can be measured using fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI). Amyloid deposition can be determined in vivo using Pittsburgh compound B ([11C]PiB) positron emission tomography (PET). We aimed to elucidate the association between WMH and the progression of amyloid deposition in patients with AD. Twenty-two patients with probable AD underwent FLAIR-MRI and [11C]PiB-PET examinations at baseline (BL) and after a mean follow-up (FU) interval of 28 months. The relationship between BL-WMH and the progression of cerebral amyloid between BL and FU was examined using a regions-of-interest (ROI) approach. The region-specific variability of this relationship was analyzed using a voxel-based method. The longitudinal analysis revealed a statistically significant association between the amount of BL-WMH and the progression of amyloid load between BL and FU (p = 0.006, adjusted R2 = 0.375, standardized coefficient β = 0.384). The association was particularly observed in parieto-occipital regions and tended to be closer in regions adjacent to the brain surface. According to our knowledge, this is the first in vivo study in human being supporting the hypothesis that impaired amyloid clearance along perivascular drainage pathways may contribute to β-amyloid deposition in sporadic AD. The extent of WMH might be a relevant factor to be assessed in antiamyloid drug trials.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  Yaakov Stern,et al.  Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. , 2008, Archives of neurology.

[3]  C. Patlak,et al.  Drainage of interstitial fluid from different regions of rat brain. , 1984, The American journal of physiology.

[4]  A. Hofman,et al.  Cerebral white matter lesions and the risk of dementia. , 2004, Archives of neurology.

[5]  R. Weller Pathology of Cerebrospinal Fluid and Interstitial Fluid of the CNS: Significance for Alzheimer Disease, Prion Disorders and Multiple Sclerosis , 1998, Journal of neuropathology and experimental neurology.

[6]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[7]  G. Waldemar,et al.  The apolipoprotein E ɛ4‐allele and antihypertensive treatment are associated with increased risk of cerebral MRI white matter hyperintensities , 2007 .

[8]  U Seligsohn,et al.  Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. , 1997, Clinical chemistry.

[9]  M Schwaiger,et al.  Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease , 2009, Neurology.

[10]  D. Thal The Precapillary Segment of the Blood-Brain Barrier and Its Relation to Perivascular Drainage in Alzheimer's Disease and Small Vessel Disease. , 2009, TheScientificWorldJournal.

[11]  J. Hoffman,et al.  FDG PET imaging in patients with pathologically verified dementia. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[13]  A. Drzezga,et al.  Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid , 2009, Biological Psychiatry.

[14]  P. Scheltens,et al.  A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging , 1993, Journal of the Neurological Sciences.

[15]  J. Morris,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.

[16]  W. Klunk,et al.  Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ε4 Genotype in Alzheimer's Disease , 2010, Biological Psychiatry.

[17]  Jan Cees de Groot,et al.  Interaction Between Hypertension, apoE, and Cerebral White Matter Lesions , 2004, Stroke.

[18]  Lisa A. Weissfeld,et al.  Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.

[19]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[20]  W. W. Zhang,et al.  Could changes in arterioles impede the perivascular drainage of interstitial fluid from the cerebral white matter in leukoaraiosis? , 2010, Neuropathology and applied neurobiology.

[21]  Timo Grimmer,et al.  Clinical severity of Alzheimer's disease is associated with PIB uptake in PET , 2009, Neurobiology of Aging.

[22]  L. Pantoni Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges , 2010, The Lancet Neurology.

[23]  David M Holtzman,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[24]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[25]  E. Zhang,et al.  Directional and compartmentalised drainage of interstitial fluid and cerebrospinal fluid from the rat brain , 2004, Acta Neuropathologica.

[26]  Satoshi Minoshima,et al.  Imaging Alzheimer's disease: clinical applications. , 2003, Neuroimaging clinics of North America.

[27]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[28]  C. DeCarli,et al.  What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? , 2007, Neurology.

[29]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[30]  R O Weller,et al.  Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology , 2008, Neuropathology and applied neurobiology.

[31]  Marie-Claude Potier,et al.  Classification and basic pathology of Alzheimer disease , 2009, Acta Neuropathologica.

[32]  C. Sudlow,et al.  Genetic Determinants of White Matter Hyperintensities on Brain Scans: A Systematic Assessment of 19 Candidate Gene Polymorphisms in 46 Studies in 19 000 Subjects , 2009, Stroke.

[33]  Keith A. Johnson,et al.  Imaging of amyloid burden and distribution in cerebral amyloid angiopathy , 2007, Annals of neurology.